The prognostic utility of preoperative β2 microglobulin in patients with renal cell carcinoma.

• DOI: 10.1200/jco.2025.43.5_suppl.565
• Publication Date: 2025-02-18T14:35:11Z
• Authors: Gregory Palmateer; Edouard Nicaise; Taylor Goodstein; Dattatraya H. Patil; Shreyas Joshi; Vikram M. Narayan; Kenneth Ogan; Viraj A. Master
• Keywords: Beta-2 microglobulin

565 Background: β2 microglobulin is a nonglycosylated protein synthesized by all nucleated cells. It has been utilized as tumor marker in several different malignancies, however, studies examining its role renal cell carcinoma (RCC) are limited. Methods: Using the Emory kidney cancer database, patients with any stage or histology RCC who underwent partial radical nephrectomy from 2000 to 2022 and had an available within 90 days before surgery were included. ≥ 2.34 mg/L was considered elevated. Patient surgical characteristics recorded. Kaplan-Meier curves multivariable Cox hazards models used assess association between elevated overall (OS) cancer-specific survival (CSS). Subgroup analysis performed based on function (estimated glomerular filtration rate (eGFR) ≤ > 60 mL/min/1.73m 2 ) metastatic disease status. Results: Of 429 met inclusion criteria, 178 (41.5%) preoperative microglobulin. After adjusting for confounders, independently associated worse CSS (HR 2.08 [95% CI 1.20–3.60]; p = 0.009) OS 1.58 1.03–2.41]; 0.035) compared normal On subgroup analysis, remained significantly OS/CSS only non-metastatic (Table). Conclusions: A preoperatively level undergoing nephrectomy. The utility of prognostic indicator most relevant disease. Multivariable model effect according Covariants n(%) Cancer-specific SurvivalHazard Ratio (95% CI) p-value Overall 102 (63) 0.95 (0.51-1.76) 0.872 0.93 (0.56-1.55) 0.779 76 (28.5) 4.55 (1.24-16.77) 0.023 2.99 (1.37-6.54) 0.006 eGFR 60* 99 (23.1) 1.31 (0.69-2.49) 0.410 1.51 (0.95-2.41) 0.083 79 (18.4) 2.90 (1.54-5.44) < 0.001 2.00 (1.19-3.36) 0.009 50 (11.7) 1.24 (0.55-2.78) 0.600 1.39 (0.74-2.60) 0.309 201 (46.9) Ref *Calculated using Chronic Kidney Disease Epidemiology Collaboration 2021 equation. Variables include age, sex, race, Body Mass Index (BMI), Charlson Comorbidity (CCI) pT stage, Fuhrman grade, presence IVC thrombus, receipt systemic therapy, IMDC risk score (metastatic only).